We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+45.82%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$946M
AUM Growth
+$115M
Cap. Flow
-$111M
Cap. Flow %
-11.78%
Top 10 Hldgs %
89.29%
Holding
20
New
–
Increased
5
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$13.6M
2
ATXS
Astria Therapeutics
ATXS
+$9.14M
3
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$6.72M
4
AXSM icon
Axsome Therapeutics
AXSM
+$1.26M
5
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$597K

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$33.7M
2
NUVL
Nuvalent
NUVL
+$32.6M
3
IMVT icon
Immunovant
IMVT
+$28.8M
4
MRUS
Merus
MRUS
+$27.2M
5
TRVI icon
Trevi Therapeutics
TRVI
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$12.3B
$188M 19.85%
2,360,077
+18,839
+0.8% +$1.26M
IMGN
2
DELISTED
Immunogen Inc
IMGN
$176M 18.58%
5,929,592
– –
NUVL
3
DELISTED
Nuvalent
NUVL
$142M 14.96%
1,924,626
-527,193
-22% -$32.6M
APGE icon
4
Apogee Therapeutics
APGE
$10.2B
$82.2M 8.68%
2,941,176
– –
RYZB
5
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$77.5M 8.18%
1,245,929
+24,025
+2% +$597K
KNSA icon
6
Kiniksa Pharmaceuticals
KNSA
$4.97B
$50.6M 5.34%
2,883,221
+408,660
+17% +$6.72M
ARGX icon
7
argenx
ARGX
$56.1B
$43M 4.54%
112,903
+29,156
+35% +$13.6M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.2B
$29.8M 3.15%
1,369,623
– –
ELVN icon
9
Enliven Therapeutics
ELVN
$3.8B
$29.5M 3.12%
2,131,369
– –
ATXS
10
DELISTED
Astria Therapeutics
ATXS
$27.3M 2.88%
3,554,129
+1,652,732
+87% +$9.14M
COGT icon
11
Cogent Biosciences
COGT
$6.91B
$20.9M 2.21%
3,558,975
– –
DNTH icon
12
Dianthus Therapeutics
DNTH
$5.78B
$20.1M 2.12%
1,928,503
– –
MRUS
13
DELISTED
Merus
MRUS
$19.7M 2.08%
717,254
-1,164,091
-62% -$27.2M
TYRA icon
14
Tyra Biosciences
TYRA
$1.89B
$19.3M 2.04%
1,393,329
– –
TERN
15
DELISTED
Terns Pharmaceuticals
TERN
$13.2M 1.4%
2,040,000
– –
SYRE icon
16
Spyre Therapeutics
SYRE
$8.7B
$8.14M 0.86%
378,421
– –
DBVT
17
DBV Technologies
DBVT
$813M
– –
-678,115
Closed -$9.22M
IMVT icon
18
Immunovant
IMVT
$8.28B
– –
-750,000
Closed -$28.8M
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
– –
-1,142,473
Closed -$33.7M
TRVI icon
20
Trevi Therapeutics
TRVI
$2.57B
– –
-5,163,287
Closed -$11.3M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q4 2023 Portfolio in Review

As of Q4 2023, Fairmount Funds Management held 20 positions worth $946M, up 14% from $831M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Fairmount Funds Management withdrew a net $111M in Q4 2023, closing 4 positions and reducing 2 holdings. Its most notable exit was Soleno Therapeutics, an estimated $33.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Fairmount Funds Management added an estimated $13.6M to argenx.

  • Fairmount Funds Management added most to argenx in Q4 2023, an estimated $13.6M increase.
  • Fairmount Funds Management's biggest Q4 2023 reduction was Nuvalent, cutting an estimated $32.6M.
  • Fairmount Funds Management fully exited Soleno Therapeutics in Q4 2023, selling an estimated $33.7M.
  • Fairmount Funds Management's ten largest holdings make up 89% of its $946M portfolio in Q4 2023.
  • Fairmount Funds Management opened 0 new positions and closed 4 in Q4 2023.
  • Fairmount Funds Management's portfolio value rose 14% quarter-over-quarter to $946M.

Based on Fairmount Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.